Emily M. Leproust - Jul 22, 2021 Form 4 Insider Report for Sema4 Holdings Corp. (WGSWW)

Role: Director
Signature: /s/ Daniel Clark, Attorney-in-Fact
Stock symbol: WGSWW
Transactions as of: Jul 22, 2021
Transactions value $: $1,916,659
Form type: 4
Date filed: 7/26/2021, 06:48 PM
Previous filing: Jul 14, 2021
Next filing: Jul 27, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	WGSWW	Class A Common Stock	Conversion of derivative security	$0	+25K		$0.00	25K	Jul 22, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	WGSWW	Class B Common Stock	Conversion of derivative security		-25K	-100%		0	Jul 22, 2021	Class A Common Stock	25K		Direct	F1
transaction	WGSWW	Private Placement Warrants	Award	$1.92M	+167K		$11.50	167K	Jul 22, 2021	Class A Common Stock	167K	$11.50	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.
F2	In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of $11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock.

Content

In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of $11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock.